3 Penny Stocks With Market Caps Larger Than $100M To Consider
null
Protalix BioTherapeutics, Inc. Q1 2026 Earnings Call Summary
null
PLX: Chiesi Milestone Received
null
Company to host conference call and webcast today at 8:00 a.m. EDT Elfabrio commercial execution continues following European Commission approval of the 2...
null
Protalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlights: Strong Financial Position ...
null
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
null
Transcript: Protalix BioTherapeutics Q1 2026 Earnings Conference Call
null
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and...
null
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026
null
DISCLOSURE FISCAL 2026/24 OF TRANSACTIONS ON TREASURY SHARES
null
Pluxee delivers strong margin expansion and cash generation in H1 Fiscal 2026, reaffirming all full‑year objectives
null
DISCLOSURE FISCAL 2026/23 OF TRANSACTIONS ON TREASURY SHARES
null
April 2026 Penny Stocks With Promising Potential
null
DISCLOSURE FISCAL 2026/22 OF TRANSACTIONS ON TREASURY SHARES
null
A Look At Pluxee (ENXTPA:PLX) Valuation After Recent Share Price Weakness
null
DISCLOSURE FISCAL 2026/21 OF TRANSACTIONS ON TREASURY SHARES
null
DISCLOSURE FISCAL 2026/20 OF TRANSACTIONS ON TREASURY SHARES
null
Protalix: Q4 Earnings Snapshot
null
Protalix BioTherapeutics Inc (PLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ...
null
PLX: 2025 Full Year Results
null
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
null
Company to host conference call and webcast today at 8:00 a.m. EDT The European Commission (EC) approved the 2mg/kg every-4-weeks (E4W) dosing regimen for...
null
Protalix BioTherapeutics advances Fabry disease and gout programs during 2025
null
DISCLOSURE FISCAL 2026/19 OF TRANSACTIONS ON TREASURY SHARES
null
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and...
null
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026
null
Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen
null
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) ▼
null
3 Promising Penny Stocks With Market Caps Up To $400M
#Product Stage
PLX: CHMP Delivers Positive Opinion
#Product Stage #Partners
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
#Product Stage
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU
#Product Stage #Partners
Baozun And 2 Other Promising Penny Stocks
undefined
Protalix BioTherapeutics Letter to Stockholders
#Product Stage #Partners #Acquisition
PLX: Secarna’s Antisense Oligonucleotide Discovery Collaboration
#Partners
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement
#Partners
PLX: Protalix Seeks Re-Examination of CHMP Opinion
#Product Stage #Management Changes #Customers
Protalix BioTherapeutics, Inc. Q3 2025 Earnings Call Summary
null
Protalix BioTherapeutics Inc (PLX) Q3 2025 Earnings Call Highlights: Navigating Revenue ...
#Product Stage #FDA approved/pending approval
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization...
#Product Stage #Customers #Partners #FDA approved/pending approval
Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results
#Product Stage #Customers #FDA approved/pending approval
Protalix: Q3 Earnings Snapshot
undefined
Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025
#Customers #Partners #FDA approved/pending approval
Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU
#Product Stage
3 Compelling Penny Stocks With Market Caps Under $600M
#Product Stage #FDA approved/pending approval
Can Protalix (PLX) Turn Regulatory Setbacks Into a Competitive Advantage in Rare Disease Markets?
#FDA approved #Product Stage #Partners
Protalix BioTherapeutics (PLX): Evaluating Valuation After EMA Setback on Elfabrio Dosing Regimen
undefined
Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU
#Product Stage #Customers
Protalix BioTherapeutics, Inc. (PLX) Gains Investor Confidence With Major Stake Increase
#Investment
3 Penny Stocks With Market Caps Over $30M To Consider
#Management Changes
Presenting at the Investor Summit Q3 2025 on September 16; Watch the Live Stream for Free
undefined
Protalix BioTherapeutics to Present at Investor Summit Virtual
#Management Changes #Partners #FDA approved
Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
#Partners #FDA approved
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of...
#FDA approved/pending approval #Partners #Product Stage
PLX: New CFO to Take the Reins
#Management Changes #Customers #Product Stage
Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results
#Customers #Partners #Management Changes
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization...
#Product Stage #Partners #FDA approved/pending approval
Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025
#Product Stage #Customers #Partners #FDA approved/pending approval
Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer
#Management Changes
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization...
#Management Changes #Partners #FDA approved
Fabry Disease Treatment Analysis Report 2025 | Market to Reach $3.86 Billion by 2030, Rising Fabry Disease Prevalence and Demand for Targeted Therapies Drive Growth
#Product Stage #FDA approved/pending approval
Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes®
undefined
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization...
#Partners #FDA approved/pending approval
Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
#Partners #FDA approved/pending approval
PLX: First Quarter Results
#Customers #Product Stage
Protalix BioTherapeutics Inc (PLX) Q1 2025 Earnings Call Highlights: Revenue Surge and ...
#Product Stage #Customers #Partners
Protalix: Q1 Earnings Snapshot
undefined
Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results
#Product Stage #Partners
Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025
undefined
Top Penny Stocks To Watch In April 2025
#Public Trading
Protalix BioTherapeutics And 2 Other Promising Penny Stocks
undefined
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization...
#Partners #FDA approved/pending approval
Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025
#FDA approved/pending approval #Partners
Is Protalix BioTherapeutics (PLX) The High Growth Low Debt Stock to Invest in Now?
undefined
iAccess Alpha's Virtual Best Ideas Spring Investment Conference March 25-26, 2025
undefined
Protalix BioTherapeutics Inc (PLX) Q4 2024 Earnings Call Highlights: Record Revenue Growth ...
#Customers #Partners #Product Stage
PLX: 2024 Results
#Product Stage #Customers #Partners #PIPE/PO
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization...
undefined
Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results
#Customers #Product Stage #Partners
Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025
#FDA approved/pending approval #Partners
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization...
undefined
3 US Penny Stocks With Market Caps Under $400M To Watch
#Partners
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of...
#Partners #FDA approved/pending approval
Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference
#Partners #FDA approved/pending approval
PLX: Revisiting the Thesis
#Product Stage #Partners #FDA approved/pending approval
US Penny Stocks: Arbe Robotics And 2 More Promising Picks
#Partners
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-American: PLX), a biopharmaceutical company focused on the development, production and commercialization...
#Partners
Protalix BioTherapeutics Issues 2025 Letter to Stockholders
#Partners #Customers
EMA validates Chiesi and Protalix’s dose variation for Fabry disease
#Partners
Promising US Penny Stocks To Watch In December 2024
undefined
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa
#Partners
Protalix BioTherapeutics Inc (PLX) Q3 2024 Earnings Call Highlights: Revenue Surge and ...
#Customers
PLX: Self-Sustaining Rise to Lead in Renal Rare Disease
#Customers
Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results
undefined
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-American: PLX), a biopharmaceutical company focused on the development, production and commercialization...
#Customers #Partners
Protalix: Q3 Earnings Snapshot
undefined
Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024
undefined
Accolade And 2 Other Penny Stocks To Watch On US Exchanges
undefined
Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024
undefined
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of...
#Partners
OTC Markets Hosts Virtual Investor Presentation with Dror Bashan, President & CEO of Protalix Biotherapeutics, and John Vandermosten, Senior Analyst at Zacks SCR
#Customers #Partners
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
#Partners
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
#Partners
Protalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024
#Partners
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization...
#Partners
Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
#Partners
Protalix BioTherapeutics Announces Repayment of Outstanding Senior Secured Convertible Promissory Notes
#Investment #Partners
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization...
#Investment #Partners
Is Protalix BioTherapeutics, Inc. (PLX) The Best Rated Penny Stock To Buy According to Analysts?
#Customers #Partners
PLX: A Focus on Renal Rare Disease
#Customers #Partners #Management Changes
Protalix: Q2 Earnings Snapshot
#Investment
Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results
#Investment #Customers #Partners
Protalix BioTherapeutics to Announce Second Quarter 2024 Financial and Business Results on August 14, 2024
#Management Changes
Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout
#Partners
Protalix BioTherapeutics to Present at the 2024 BIO International Convention
#Management Changes #Partners
PLX: First Quarter Update
#Customers #Partners #Expand
Protalix BioTherapeutics Inc (PLX) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
#Customers #Investment
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2024 Earnings Call Transcript
#Customers #Partners #Management Changes
Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results
#Investment
Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024
#Management Changes
PLX: Elfabrio Geographic Expansion
#Customers #Partners #Expand
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript
#Customers #Partners #Management Changes
Protalix BioTherapeutics Inc Reports Revenue Growth and Net Income Gain in FY 2023
null
Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results
#Customers #Partners
Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024
#Partners
Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference
#Partners
Protalix BioTherapeutics Issues 2024 Letter to Stockholders
#Partners #Customers
Levicept Appoints Eliot Forster as CEO
#Management Changes
PLX: More Regulatory Approvals
#Management Changes
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2023 Earnings Call Transcript
#Customers #Partners #Management Changes
Protalix BioTherapeutics Inc (PLX) Reports Q3 2023 Financial Results
#Customers
Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results
#Customers #Partners #Management Changes
Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023
#Management Changes
Protalix BioTherapeutics Issues Statement Regarding Security Situation in Israel
#Partners
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors
#Management Changes
Protalix BioTherapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
#Management Changes #Partners
PLX: Second Quarter Results
#Customers #Partners #Investment
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q2 2023 Earnings Call Transcript
#Customers #Partners #Investment
Protalix BioTherapeutics Reports Second Quarter 2023 Financial and Business Results
#Customers #Partners #Investment
Protalix BioTherapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
#Management Changes
Protalix BioTherapeutics to Announce Second Quarter 2023 Financial and Business Results on August 7, 2023
undefined
Protalix BioTherapeutics to Host In-Person KOL Breakfast following the Approval of Elfabrio® in both the United States and the European Union for Adults with Fabry Disease
#Partners
Protalix BioTherapeutics Issues Letter to Stockholders
#Customers #Partners
PLX: Back of the Envelope
#Customers #Partners #Investment
Protalix BioTherapeutics set to join Russell 3000® Index
#Public Trading
Protalix BioTherapeutics Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases
#Partners
PLX: FDA Approval of Elfabrio
#Customers
Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics
undefined
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease
undefined
FDA Approves Fabry Disease Treatment from Chiesi, Protalix | BioSpace
#Partners
Weekly biotech pulse: Big catalysts on tap for Sarepta, Roche, Eyenovia, and more
undefined
PLX: One Down, One to Go
undefined
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
undefined
Protalix BioTherapeutics Reports First Quarter 2023 Financial and Business Results
#Customers #Partners
Protalix BioTherapeutics to Announce First Quarter 2023 Financial and Business Results on May 4, 2023
#Investment
Protalix BioTherapeutics Announces First Patient Dosed in First in Human Phase I Clinical Trial of PRX-115 for the Treatment of Severe Gout
#Investment
Protalix BioTherapeutics Issues Statement Related to Silicon Valley Bank and Signature Bank
#Partners
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2022 Earnings Call Transcript
undefined
PLX: May is a Big Month
undefined
Protalix BioTherapeutics Reports Fiscal Year 2022 Financial and Business Results
#Customers #Partners
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease
undefined
Protalix BioTherapeutics to Participate in the 19th Annual WORLDSymposium™ 2023
#Partners #Customers
Protalix BioTherapeutics to Delist its Common Stock from the Tel Aviv Stock Exchange
#Public Trading
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of a Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
#Customers
Protalix BioTherapeutics to Present in Person at the H.C. Wainwright 24th Annual Global Investment Conference
#Investment #Partners
Protalix BioTherapeutics Reports Second Quarter 2022 Financial and Business Results
#Management Changes #Investment
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease
#Partners
Protalix BioTherapeutics Reports Fiscal Year 2021 Financial and Business Results
#Investment #Partners
Protalix BioTherapeutics Reports Third Quarter 2021 Financial Results and Provides Financial and Business Update
#Investment #Partners
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease
#Partners #Expand
Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA
#Customers
Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA
#Customers
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Four Weeks for Treatment of Fabry Disease
#Partners
Protalix BioTherapeutics Completes Raise of Approximately $40 Million in Gross Proceeds
#Investment
Protalix BioTherapeutics Enters into an Exclusive Partnership with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled Delivery
#Partners
Protalix BioTherapeutics Announces Proposed Public Offering of Common Stock
#Investment
Protalix BioTherapeutics Issues 2020 Letter to Shareholders
#Partners #Investment #Management Changes
FDA Extends Review Date to April for US Approval of PRX-102
#Customers
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
#Customers
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Launch of Expanded Access Program in the United States for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
#Customers
Protalix BioTherapeutics Regains Compliance with NYSE American Continued Listing Standards
#Public Trading
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of Biologics License Application (BLA) for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease and Grants Priority Review
#Customers
Protalix BioTherapeutics Appoints Yael Hayon, Ph.D. as its New Vice President, Research and Development
#Management Changes
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease
#Partners #Customers
Protalix BioTherapeutics Raises $43.7M in Financing - FinSMEs
#Investment
Protalix BioTherapeutics and Chiesi Farmaceutici Announce Receipt of "Agreement Letter" for Initial Pediatric Study Plan for PRX-102 for the Treatment of Fabry Disease
#Partners
Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors
#Management Changes
Protalix BioTherapeutics and Chiesi Farmaceutici Announce Successful pre-BLA Meeting with FDA for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States
#Investment #Partners
Protalix up 74% after positive Fabry disease trial results
#Customers
Protalix BioTherapeutics and Chiesi Group Complete Enrollment in the Third Phase III Clinical Trial of pegunigalsidase alfa (PRX‑102) for the Treatment of Fabry Disease
#Partners
Protalix BioTherapeutics Focuses on Evaluating and Pursuing Alternatives to Maximize Shareholder Value through Refinancing & Strategic Partnerships
#Partners #Expand
Shlomo Yanai Resigns as Chairman of the Board of Protalix BioTherapeutics
#Management Changes
Protalix BioTherapeutics Appoints Eyal Rubin as its New Senior Vice President and Chief Financial Officer
#Management Changes
Protalix BioTherapeutics Completes Enrollment in the Phase III BRIGHT Clinical Trial of pegunigalsidase alfa (PRX 102) for the Treatment of Fabry Disease
#Customers
Protalix BioTherapeutics and Chiesi Farmaceutici S.p.A to Apply for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States
#Investment
Protalix BioTherapeutics Appoints Dror Bashan as its New President and Chief Executive Officer and Director
#Management Changes
Protalix BioTherapeutics Enters into an Exclusive Ex-US Partnership with Chiesi Farmaceutici for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
#Partners
Pfizer Invests $10M In Protalix, Pays $36M For Commercial Rights
#Investment #Partners
Protalix flips its Gaucher drug to Pfizer for $46M in R&D cash
undefined